论文部分内容阅读
目的:探讨西格列汀联合格列齐特缓释片对2型糖尿病（T2DM）患者血糖、血脂及胰岛β细胞功能的影响。方法:纳入2017年10月至2019年10月本院收治的T2DM患者88例，随机分为对照组（n n=44）和观察组（n n=44）。对照组给予格列齐特缓释片治疗，观察组在对照组基础上加用西格列汀治疗。记录治疗前、治疗16周后两组血糖、糖化血红蛋白（HbA1c）、空腹胰岛素（FINS）、血脂、血清葡萄糖转运蛋白4（GLUT4）水平，检测两组胰岛β细胞功能及血管内皮功能变化。n 结果:治疗后两组空腹血糖（FPG）、餐后2h血糖（2hPG）及HbA1c较治疗前降低，FINS较治疗前升高（均n P<0.05）。治疗后两组血甘油三脂（TG）、总胆固醇（TC）、低密度脂蛋白（LDL-C）较治疗前降低，高密度脂蛋白（HDL-C）较治疗前升高（均n P<0.05）。治疗后两组稳态模型β细胞功能指数（HOMA-β）较治疗前升高，稳态模型胰岛素抵抗指数（HOMA-IR）较治疗前降低（均n P<0.05）。治疗后观察组血清GLUT4水平高于治疗前，两组内皮依赖性血管舒张功能（EDD）较治疗前均显著增加，且治疗后观察组上述指标均显著优于对照组（均n P<0.05）。n 结论:西格列汀联合格列齐特缓释片治疗T2DM，能明显降低血糖水平，改善血脂异常和胰岛β细胞功能，修复血管内皮功能损伤，临床疗效确切。“,”Objective:To investigate the effects of sitagliptin and gliclazide sustained-release tablets on blood glucose, blood lipids and islet β-cell function in patients with type 2 diabetes (T2DM) .Methods:Eighty-eight patients with T2DM admitted to our hospital between October 2017 and October 2019 were randomly divided into the control group and study group (n n=44 each) . The control group was treated with gliclazide sustained-release tablets. In addition, the study group was treated with sitagliptin. The levels of blood glucose, glycated hemoglobin (HbA1c) , fasting insulin (FINS) , blood lipids, and serum glucose transporter 4 (GLUT4) were recorded at baseline and at 16 weeks after the treatment in the two groups. The changes in islet β cell function and vascular endothelial function were examined in the two groups.n Results:After the treatment, the levels of fasting plasma glucose (FPG) , postprandial 2 h plasma glucose (2hPG) and HbA1c in the two groups decreased compared with those at baseline, whereas the FINS increased compared with that at baseline (all n P<0.05) ; the levels of plasma triglyceride (TG) , total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in the two groups decreased compared with those at baseline, whereas the level of plasma high-density lipoprotein cholesterol (HDL-C) increased compared with that at baseline (alln P<0.05) ; the homeostasis model assessment for β cell function (HOMA-β) index in the two groups increased compared with that at baseline, whereas the homeostasis model assessment for insulin resistance (HOMA-IR) index decreased compared with that at baseline (both n P<0.05) ; the serum GLUT4 level was higher than that at baseline in the study group, and the endothelium-dependent dilation function (EDD) significantly increased compared with that at baseline in the two groups; and the indicators in the study group were significantly better than those in the control group (all n P<0.05) .n Conclusion:Sitagliptin and gliclazide sustained-release tablets in the treatment of T2DM may significantly reduce blood glucose level, improve dyslipidemia and islet β-cell function, and repair the damage of vascular endothelial function, with significantly clinical effect.